Keyword: Japan

Ajinomoto Bio-Pharma Services has concluded a deal that will allow the CDMO to operate in the gene therapy space.

Opdivo, the Bristol-Myers cancer drug co-developed with Japan’s Ono, is a global cash cow—but a Nobel winner behind the drug isn't happy with his cut.

AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.

Roche’s Xofluza has yet to see widespread uptake in the U.S., and new reports of resistance in Japan won’t help the drug’s case.

The global recall of valsartan has now extended to Pfizer and to Japan, via Mylan and India.

Takeda will probably not sell its OTC business to help pay off the $31 billion loan it’s taking to finance the Shire takeover, its CEO says.

With its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with manufacturing sites in the U.S. and Japan.  

Takeda CEO Christophe Weber and Nissan's now-fallen chairman Carlos Ghosn have much more in common than their French nationality.

Sun Pharma is picking up two manufacturing plants and a portfolio of dermatology drugs in Japan for just $1 million.

The deal follows a flurry of consumer deals and comes as J&J's beauty products have been delivering strong growth, thanks in part to Ci:z.